Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer

Breast Cancer Research

Volumn 2, Issue 6, 2000, Pages 430-435

  Clare, Susan E ^a   Nakhlis, Faina ^a   Panetta, John Carl ^b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Breast cancer; Chemotherapy; Mathematical models; Metastasis; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HYPOTHESIS; MATHEMATICAL MODEL; METASTASIS; MOLECULAR BIOLOGY; PREDICTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MASTECTOMY; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; REPRODUCIBILITY OF RESULTS; STOCHASTIC PROCESSES; TIME FACTORS;

EID: 0034469339     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr90     Document Type: Review

References (43)

1. Cancer undefeated
2. Cancer statistics, 1999
3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
4. The curability of breast cancer
5. The curability of breast cancer
6. The curability of breast cancer
7. Long term survival analysis: The curability of breast cancer
8. Dormancy of mammary carcinoma after mastectomy
9. Annual hazard rates of recurrence for breast cancer after primary therapy
10. On mathematical modeling of critical variables in cancer treatment (goals: Better understanding of the past and better planning in the future)
11. Computer simulation of a breast cancer metastasis model
12. A stochastic numerical model of breast cancer growth that simulates clinical data
13. The Norton-Simon hypothesis revisited
14. Tumor size, sensitivity to therapy, and design of treatment schedules
15. Growth curve of an experimental solid tumor following radiotheraphy
16. Decelerating growth and human breast cancer
17. Mammographic assessment of human breast cancer growth and duration
18. A simulation model of the natural history of human breast cancer
19. Predicting the course of Gompertzian growth
20. Natural history of untreated breast cancer (1805-1933) comparison of untreated and treated cases according to historical grade of malignancy
21. Kinetics of tumor growth and regression in IgG multiple myeloma
22. Growth rates of primary breast cancer
23. Is Gompertzian or exponential kinetics a valid description of individual human cancer growth?
24. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
25. New perspectives in clinical oncology from angiogenesis research
26. Fighting cancer by attacking its blood supply
27. Angiogenesis in cancer, vascular, rheumatoid and other disease
28. A Gompertzian model of human breast cancer growth
29. Re: Larry Norton, a Gompertzian model of human breast cancer growth
30. Report of the international workshop on screening for breast cancer
31. Experimental evaluation of potential anticancer agents: XIII. On the criteria and kinetics associated with 'curability' of experimental leukemia
32. Mutations of bacteria from virus sensitivity to virus resistance
33. Origin of the resistance of leukaemic cells to folic acid antagonists
34. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
35. Rationale for the use of alternating non-cross-resistant chemotherapy
36. A mathematical model of drug resistance: Heterogeneous tumors
37. Computer model challenges breast cancer treatment strategy
38. Proposal for a new model of breast cancer metastatic development
39. An alternative approach for treatment of breast cancer
40. Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'
41. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes
42. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients